<DOC>
	<DOCNO>NCT02573155</DOCNO>
	<brief_summary>This phase I , randomise , placebo-controlled 2-part study ass safety , tolerability , pharmacokinetics pharmacodynamics AZD8871 deliver inhalation , asthmatic chronic obstructive pulmonary disease ( COPD ) subject .</brief_summary>
	<brief_title>Two-part Safety , Tolerability , Pharmacodynamic -Kinetic Study Inhaled AZD8871 Asthmatic COPD Subjects</brief_title>
	<detailed_description>This study integrate Phase I protocol divide 2 part . Part 1 : single ascend dose study ( 6 AZD8871 dose level ) 16 male subject mild asthma . AZD8871 administer ( Genuair® inhaler ) supervision study centre , accord randomisation scheme Part 2 : 5 treatment period single dose study ( AZD8871 [ two dos ] , indacaterol , tiotropium placebo ) 40 male non-childbearing female subject moderate severe COPD . Each treatment period separate washout period least 7 day . The primary comparison bronchodilation AZD8871 dose placebo .</detailed_description>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Part 1 1 . Subjects able willing provide write informed consent prior conduct studyrelated procedure , include withdrawal medication 2 . Adult male subject age 18 70 year ( inclusive ) 3 . Body mass index ( BMI ) 18 32 kg/m2 screen 4 . Clinical diagnosis asthma ( accord Global Initiative Asthma [ GINA ] guideline ) least 6 month prior screen 5 . Ability change current asthma therapy , discontinue previous prescribed medication signature inform consent per require washout period 6 . Screening FEV1 value ≥70 % predict normal value 7 . FEV1 reversibility ≥12 % absolute increase least 200 mL baseline value within 30 min inhalation 400 µg ( 4 puff ) salbutamol via meter dose inhaler , spacer device 8 . Subjects use intermittent salbutamol / subject stable dose low dose Inhaled corticosteroid ( defined GINA guideline ) least 4 week prior screen 9 . Predose FEV1 value first treatment period within range ± 20 % FEV1 measure screen prior salbutamol inhalation 10 . No current smoker , subject smoke history last 12 month subject total smoke history 10 packyears 11 . No relevant pulmonary disease history thoracic surgery 12 . Subjects otherwise healthy determine medical history , physical examination , 12lead ECG finding 13 . Normal blood pressure ( define Systolic blood pressure [ SBP ] 100 140 mmHg subject ≤59 year age 100 150 mmHg subject ≥60 year age , Diastolic blood pressure [ DBP ] 40 90 mmHg ) screen 14 . Subjects whose clinical laboratory test result clinically relevant acceptable Investigator . 15 . Subjects negative hepatitis B surface antigen ( HBsAg ) , hepatitis B core ( HBc ) antibody ( IgM ) , hepatitis C antibody human immunodeficiency virus ( HIV ) I II antibody screen 16 . Subjects negative drug abuse alcohol test screen admission 17 . Subjects able perform repeatable pulmonary function test FEV1 accord American Thoracic Society ( ATS ) / European Respiratory Society ( ERS ) 2005 ( 9 ) criterion screen Part 2 1 . Adult male nonchildbearing female subject age ≥40 year clinical diagnosis stable moderate severe COPD accord GOLD guideline screen 2 . Females must nonchildbearing potential , confirm screen fulfilling study predefined criterion 3 . Postsalbutamol FEV1 &lt; 80 % ≥30 % predict normal value postsalbutamol FEV1 / force vital capacity ( FVC ) &lt; 70 % 4 . BMI &lt; 40 kg/m2 screen 5 . Ability change current COPD therapy , discontinue previous prescribed medication signature inform consent per require washout period 6 . Current exsmokers smoke history ≥10 pack year 7 . No evidence clinically significant respiratory / cardiovascular condition ( e.g . uncontrolled hypertension ) laboratory abnormality 8 . No relevant pulmonary disease history thoracic surgery 9 . Subjects negative HBsAg , HBc IgM , hepatitis C antibody HIV I II antibody screen 10 . Subjects able willing provide write informed consent prior conduct studyrelated procedure , include withdrawal medication 11 . Medical history must verify either personal physician medical practitioner appropriate 12 . Subjects able perform repeatable pulmonary function test FEV1 accord ATS / ERS 2005 ( 9 ) criterion screen Exclusion Criteria ( Part 1 &amp; 2 ) : 1 . Involvement plan and/or conduct study ( applies AstraZeneca staff and/or staff study site ) 2 . Previous enrolment randomisation treatment present study 3 . Current evidence recent history clinically significant unstable disease ( asthma/COPD ) abnormality could put subject risk could confound result study 4 . Subjects surgical history clinically relevant purpose study 5 . History malignancy organ system , treat untreated within past 5 year , exception localise basal cell carcinoma skin 6 . Subjects serious adverse reaction serious hypersensitivity Tiotropium ( Part 2 ) , Indacaterol ( Part 2 ) , formulation excipients ( eg , lactose ) drug pharmacologic class ( Part 1 Part 2 ) 7 . Current diagnosis COPD ( Part 1 ) history / current diagnosis asthma ( Part 2 ) 8 . Recent history asthma / COPD exacerbation require hospitalisation need increase maintenance treatment asthma / COPD within 6 week prior screen prior randomisation 9 . Use daily oxygen therapy &gt; 10 h per day ( Part 2 ) 10 . Use systemic steroid respiratory reason within 6 week prior screen 11 . Lower respiratory tract infection within 6 week prior screen prior randomisation 12 . Upper respiratory tract infection require antibiotic within 6 week prior screen prior randomisation 13 . Current history tuberculosis , bronchiectasis nonspecific pulmonary disease 14 . Subject significant cardiovascular disease may vulnerable cardiovascular instability 15 . QTcF ( QT interval correct , Fridericia formula QT [ msec ] /RR [ ] ) interval , &gt; 450 m male &gt; 470 m female screen prior randomisation , history long QT syndrome 16 . PR ( duration milliseconds begin wave P onset ventricular depolarisation [ Q R ] ) interval &gt; 200 m screen prior randomisation ( Part 1 ) Note : 4 6 hour ECG rhythm monitor telemetry perform Day1 identify patient may clinical significant abnormality prior randomisation . If occurs , patient participate study 17 . Subjects serum potassium concentration &lt; 3.5mmol/l screen 18 . Subjects history excessive use abuse alcohol within past 2 year 19 . Subjects history drug abuse within past 2 year 20 . Subjects positive drug abuse alcohol test screen prior randomisation . Subjects consume 14 ( female subject ) 21 ( male subject ) unit alcohol week 21 . Donation loss &gt; 400 ml blood plasma within previous 3 month prior screen 22 . Subjects significant infection know inflammatory process screen prior randomisation 23 . Subjects acute gastrointestinal symptom time screen prior randomisation ( eg , nausea , vomit , diarrhoea , heartburn ) 24 . Subjects acute infection influenza time screen prior randomisation 25 . Male subject agree follow instruction avoid pregnancy 26 . Subjects able adhere restriction prior concomitant medication 27 . Subjects intend use concomitant medication permit protocol undergone require washout period particular prohibit medication 28 . Subjects use investigational drug within 3 month prior screen within equivalent time 6 halflives receive last administration , whichever longer 29 . Subjects receive last dose investigational product 3 month ago extend followup 30 . Subjects unlikely cooperate requirement study , study center subject unwilling unable follow instruction principal investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>AZD8871</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>mild persistent asthma</keyword>
	<keyword>moderate severe COPD</keyword>
</DOC>